Table 1.
Treatment history and outcomes of five patients with BRAF V600E-mutant lung adenocarcinoma.
| Case number | 1st-line treatment |
2nd-line treatment |
3rd-line treatment |
4th-line treatment |
5th-line treatment |
6th-line treatment |
OS from metastasis | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T | C | R | T | C | R | T | C | R | T | C | R | T | C | R | T | C | R | ||
| 1 | CDDP + PEM PEM MAINT |
4 7 |
PR | PEMB | 3 | PD | DTX | 11 | SD | CBDCA+ nab-PTX | 3 | PD | S-1 | 2 | PD | DAB +TRA |
8.2 mo | PR | 38.5 mo |
| 2 | CDDP + VNR +RT |
4 | PR | PEM | 15 | SD | PEMB | 3 | PD | S-1 | 3 | SD | DAB +TRA |
7.9 mo | SD | CBDCA +nab-PTX |
3a | PR | 32.2 moa |
| 3 | CDDP + PEM PEM MAINT |
4 5 |
PR | DAB +TRA |
4.5 moa | PR | 12.0 moa | ||||||||||||
| 4 | PEMB | 14 | PR | CBDCA +PTX |
4 | PR | 17.9 moa | ||||||||||||
| 5 | CDDP + PEM +PEMB |
1 | NE | 1.4 mo | |||||||||||||||
Abbreviations: T = treatment regimen, C = cycles, R = response, PR = partial response, PD = progressive disease, SD = stable disease, NE = not evaluable, OS = overall survival, CDDP = cisplatin, PEM = pemetrexed, PEM MAINT = pemetrexed maintenance therapy, VNR = vinorelbine, RT = radiotherapy, PEMB = pembrolizumab, DAB = dabrafenib, TRA = trametinib, DTX = docetaxel, CBDCA = carboplatin, nab-PTX = albumin-bound paclitaxel, mo = months.
a
On going at the time of review. The database lock date was set at November 1, 2019.